CoChat

Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

A pharmacological approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small molecule inhibitors has the potential to provide novel cancer therapies for clinical use. Achieving high levels of selectivity for Cdk4/6, versus other ATP-dependent kinases, presents a significant challenge. The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks. It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro. This selectivity profile is recapitulated in cells where the most selective inhibitors create a G(1) block at concentrations up to 100-fold the IC(50) for cell proliferation. On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer.

Overview

Integrity signals

Registry

Crossref · 10.1021/jm049354h

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

1 retracted

Research works printed but not linked: 46

  1. Fisher P. M., 2003, Expert. Opin. Investig. Drugs, 12, 970
  2. Fisher P. M, 2001, Curr. Opin. Drug Discuss. Dev., 4, 634
  3. Fry D. W., 2000, Curr. Opin. Oncol., Endocrine Metab. Invest. Drugs, 2, 59
  4. Gray N., 1999, Curr. Med. Chem., 6, 875
  5. Fry D. W., 2001, J. Biol. Chem., 276, 16623
  6. Wang S., 2001, Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry
  7. Chang Y.-T., 1999, Chem. Biol., 6, 375
  8. Schow S. R., 1997, Bioorg. Med. Chem. Lett., 7, 2702
  9. Zaharevitz D. W., 1999, Cancer Res., 59, 2569
  10. Gussio R., 2000, Anti-Cancer Drug Des., 15, 66
  11. Kunick C., 2000, Bioorg. Med. Chem. Lett., 10, 569, 10.1016/S0960-894X(00)00048-2 · DOI
  12. Tang J., 2003, Bioorg. Med. Chem. Lett., 13, 2988
  13. Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 2408
  14. Misra R. N., 2003, Bioorg. Med. Chem. Lett., 13, 1136
  15. Song Y., 2002, Bioorg. Med. Chem. Lett., 12, 1132
  16. Kim K. S., 2002, J. Med. Chem., 45, 3927
  17. Furet P., 2002, Bioorg. Med. Chem. Lett., 12, 224
  18. Sielecki T. M., 2001, Bioorg. Med. Chem. Lett., 11, 1160
  19. Sasaki S., 1998, Bioorg. Med. Chem. Lett., 8, 1022
  20. Seong Y.-S., 2003, Cancer Res., 63, 7391
  21. Kim K. S., 2000, J. Med Chem., 43, 4134
  22. Li X., 2003, Bioorg. Med. Chem. Lett., 13, 1942
  23. Liu J.-J., 2003, Bioorg. Med. Chem. Lett., 13, 2468
  24. Yue E. W., 2002, J. Med. Chem., 45, 5248
  25. Lane M. E., 2001, Cancer Res., 61, 6177
  26. Andreani A., 2000, Anti-Cancer Drug Des., 15, 452
  27. Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3839
  28. Sanchez-Martinez C., 2003, Bioorg. Med. Chem. Lett., 13, 3846
  29. Zhu G., 2003, Bioorg. Med. Chem. Lett., 13, 1235
  30. Ryu C.-K., 2000, Bioorg. Med. Chem. Lett., 10, 464
  31. Honma T., 2001, J. Med. Chem., 44, 4627
  32. Honma T., 2001, J. Med. Chem., 44, 4640
  33. Jeong H.-W., 2000, Bioorg. Med. Chem. Lett., 10, 1822
  34. Zhu G., 2003, J. Med. Chem., 46, 2030
  35. Bartek J., 2003, Biochem. J., 371, 204
  36. Bartkova J., 1997, Prog. Cell Cycle Res., 3, 220
  37. Hall M., 1996, Adv. Cancer Res., 68, 108
  38. Misra R. N., 2004, Chem
  39. Kelland L. R., 2000, Exp. Opin. Invest. Drugs, 9, 2911
  40. Chao S.-H., 2001, J. Biol. Chem., 276, 31799
  41. Chao S.-H., 2000, J. Biol. Chem., 275, 28348
  42. Tetsu O., 2003, Cancer Cell, 2, 245
  43. Fry D. W., 2004, Mol. Cancer Ther., 3, 1437
  44. Meyerson M., 1994, Mol. Cell Biol., 14, 2086
  45. Fry D. W., 1994, Anticancer Drug Des., 9, 351
  46. Fry D. W., 1997, Biochem. Pharmacol., 54, 887

Cited by

See all 555

Metadata

Authors
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., Brodfuehrer, J., Choi, C., Barvian, M. R., & Fry, D. W.
Affiliations
Pfizer (United States) (US)
Corresponding author
Toogood, Peter L.
Venue
Journal of Medicinal Chemistry
Published
2005-03-02
Volume
48
Issue
7
Pages
2388-2406
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1985389450
Cited by
513
References
50
Citations by year
2026: 23 · 2025: 41 · 2024: 20 · 2023: 25 · 2022: 38 · 2021: 32 · 2020: 32 · 2019: 30 · 2018: 44 · 2017: 42 · 2016: 34 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 17
FWCI
7.78
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CDK4/6, CDK4/6 inhibitors, kinase selectivity, G1 cell cycle arrest, palbociclib, small-molecule kinase inhibitors, anticancer drug candidates, pharmacokinetics
MeSH terms
Animals, Antineoplastic Agents, Biological Availability, Humans, Male, Piperazines, Proto-Oncogene Proteins, Pyridines, Pyrimidines, Structure-Activity Relationship, Thymidine, G1 Phase, Rats, Sprague-Dawley, Cyclin-Dependent Kinases, Cell Line, Tumor, Cell Proliferation, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.